Measuring Metastatic Risk in Breast Cancer
common.study.values.description
“Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment”
The primary aim of the study is to identify genomic and circulating tumor cell (CTC) markers as biomarkers of response to chemotherapy among patients with invasive breast cancer. The secondary aim of this study is to use genomic and CTC markers to evaluate metastatic risk in breast cancer following primary treatments.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-no
Diagnostic Test - Genomic and CTC Markers
This is a non-interventional study.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
common.study.values.clinical-trial-id
NCT03709134
participant.views.study.view.id
b4xL1b
